Herpes Simplex Virus and Varicella Zoster Virus in People With HIV: Prevention and Treatment Strategies

Assessment of Needs

People with HIV (PWH) are at increased risk for complications related to herpes simplex virus (HSV) and varicella zoster virus (VZV). This webinar will review current strategies for the prevention, diagnosis, and treatment of HSV and VZV infections in PWH, including antiviral therapies, vaccination recommendations, and management considerations in the context of antiretroviral therapy.

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Describe the clinical presentation and complications of HSV and VZV infections in PWH
• Apply current evidence-based strategies for the prevention and treatment of HSV and VZV infections in PWH
• List the key considerations for vaccination and antiviral management in PWH receiving antiretroviral therapy

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, September 15, 2026, 11:30 AM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Celum reported serving as a consultant or advisor to Merck & Co., Inc. (Updated June 2, 2025)

Moderator

Dr Workowski reported no financial relationships with ineligible companies. (Updated February 20, 2026)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated March 30, 2026)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated May 12, 2026)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/